New Wave Ventures
VC Fund
London, United Kingdom
New Wave Ventures is a privately owned fund seeking the opportunity to invest for the long term in companies with significant growth potential. Their target initial investment is £500,000 to £2,000,000. They invest their own money without the need for external investors or borrowings. They are not driven by the need to service interest charges orto dispose of their investments by an artificial deadline. They do not believe in using leverage to boost their returns. They are willing to co-invest with like-minded investors, although their preference is to be the sole investor alongside owner-managers.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries New Wave Ventures invests in
Stages New Wave Ventures invests in
Countries New Wave Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.3M–$26M
- Series A
- $786k–$414M
Investment Focus
Industry
- Medical 7 (25%)
- Health Care 5 (18%)
- Internet 4 (14%)
- Biotechnology 4 (14%)
- Manufacturing 4 (14%)
Stage
- Funding Round 8 (29%)
- Series A 7 (25%)
- Seed 6 (21%)
- Series B 1 (4%)
- Series C 1 (4%)
Country
- United Kingdom 15 (54%)
- France 2 (7%)
- Australia 1 (4%)
- United States 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Clare Twemlow
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
Ian George
Chief Scientific Officer
|
Chief Scientific Officer | Total investments: 1 | Find email | |
Paul Newey
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
Tim Bullock
Co-Founder
|
Co-Founder | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neuronostics Ltd is a newly established University of Exeter (UK) spin-out, focussed on the development and commercialisation of a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP. | $4M / Seed / Jun 30, 2026 | ||
| Neubond develops wearable devices for stroke mobility rehabilitation. These devices provide autonomous assistance and therapy during daily activities, integrating rehabilitation into the patient's daily life regardless of their motor capabilities. Neubond's solutions are designed to be intuitive and effective, aiming to improve thequality of life for individuals undergoing rehabilitation. | $2M / Seed / Jun 24, 2026 | ||
| Panda Surgical is a medical equipment manufacturing company that offers surgical instruments accompanied by AI-powered software. | $1.3M / Seed / Oct 05, 2025 | ||
| Mistral AI is a platform that assembles team to develop the generative AI models. | $414.5M / Series A / Dec 10, 2023 | ||
| Poolside is an artificial intelligence platform intended to offer cutting-edge foundation concepts and infrastructure. | $26M / Seed / Aug 24, 2023 | ||
| Poolside is an artificial intelligence platform intended to offer cutting-edge foundation concepts and infrastructure. | $100M / Series A / Aug 24, 2023 | ||
| Regenerys develops and sells regenerative medicine products in the streams requiring bioprocessing and biostorage. It offers Myskin, a product for the autologous treatment of serious burns and difficult to heal wounds using cultured allegoneic cells from the patient’s own skin; and Cryoskin, a medicine for the treatment of burns using autologouscells. Regenerys also provides Adiposet, a service to facilitate better cosmetic outcomes in breast cancer surgery and other cosmetic procedures by enabling the storage and return of adipose tissue for lipomodellin. In addition, it offers third party bio-processing and bio-storage services through its laboratories. Regenerys serves NHS and private healthcare providers in the United Kingdom and other parts of Europe. It began operation in 2011, with its headquarters in Cambridge in the United Kingdom. | Nov 01, 2016 | ||
| Xerion Healthcare develop nanoparticles that are used to improve treatment of cancer. The nanoparticles are injected into tumours just prior to standard radiotherapy and act to enhance the effectiveness of the treatment, amplifying the dose of free radicals generated by the X-rays. The nanoparticles are based on titanium dioxide, a common,non-toxic, semiconductor material. Xerion Healthcare are currently developing the treatment for head and neck and pancreatic tumours. | $2M / Series A / Sep 04, 2015 | ||
| Spectromics develops a diagnostic system that helps to guide antibiotic treatment. It provides a point-of-prescription test for bacterial infections that guides the treatment of antibiotics. Spectromics began operation in 2014. Its headquarters is in Manchester in the United Kingdom. | Series A / Jun 29, 2015 | ||
| Surface Generation is a privately-owned high technology and manufacturing company headquartered in the UK and with facilities in North America and Asia. Its patented Production to Functional Specification (PtFS) technology enables manufacturers in the aerospace, automotive and consumer electronics sectors to work with composite materials, savingcosts, energy and producing significantly lighter weight products. | $4.1M / Mar 31, 2015 | ||
| See all 28 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does New Wave Ventures invest in?
New Wave Ventures invests primarily in Medical, Health Care and Internet startups, most often at Funding Round and Series A stage. Most of the 28 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is New Wave Ventures's check size?
New Wave Ventures typically joins rounds of $1.3M–$26M at Seed and $786k–$414M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds New Wave Ventures participates in.
How do I contact New Wave Ventures?
Public channels for New Wave Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at New Wave Ventures?
The team at New Wave Ventures includes Clare Twemlow (Chief Financial Officer), Ian George (Chief Scientific Officer) and Paul Newey (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
